Nathanael R. Fillmore
Topics / Cutaneous Melanoma
Topic

Cutaneous Melanoma

Fillmore has extensively investigated the epidemiology and clinical outcomes of cutaneous melanoma, with a particular focus on disparities and risk factors within the veteran population. His research identifies critical associations between melanoma risk and variables such as Parkinson's disease, Agent Orange exposure, and neighborhood-level socioeconomic deprivation. Additionally, his work examines gaps in the delivery of standard care, including sentinel lymph node biopsy utilization, and evaluates the real-world effectiveness of immune checkpoint inhibitors in patients with complex comorbidities.

U.S. Veterans and VA Data 11 VA Cancer Registry 9 Retrospective Cohort Study 5 Risk Factors 5 Melanoma Specific Survival 4 Logistic Regression 4 Epidemiology 3 Survival Analysis 3 Cox Proportional Hazards Model 3 Cancer Patients 3 SEER Database 2 Comparative Analysis 2

Publications (11)

2026

Sentinel lymph node biopsy utilization and positivity in veterans with cutaneous melanoma: A comparative analysis of the VA Cancer Registry and the SEER Program.

Daniel Y. Kim, Susan M. Swetter, Linden Huhmann, Jacqueline M. Ferguson, Kimberly Breglio, Allyson C. Spence, Lee Wheless, Mary T. Brophy, Nhan V. Do, Nathanael Fillmore‡, Rebecca I. Hartman‡‡ Equal senior authorship

Journal of the American Academy of Dermatology
U.S. Veterans and VA Data Cutaneous Melanoma VA Cancer Registry SEER Database Sentinel Lymph Node Biopsy
2026

A retrospective cohort study using the Veterans Affairs Cancer Registry database: Increased hazard of Parkinson's disease in United States Veterans with melanoma.

Linden B. Huhmann†, Jonathan C. Hwang†, David Perez, Daniel Y. Kim, Kaelyn Nannini, Nhan V. Do, John M. Gaziano, Mary T. Brophy, Lee E. Wheless, Nathanael R. Fillmore‡, Rebecca I. Hartman‡† Equal first authorship · ‡ Equal senior authorship

Journal of the American Academy of Dermatology
Cutaneous Melanoma Parkinson's Disease Retrospective Cohort Study U.S. Veterans and VA Data VA Cancer Registry
2026

Frailty and survival outcomes in veterans with invasive cutaneous melanoma: A Veterans Affairs Cancer Registry retrospective cohort study.

Linden B. Huhmann†, Jonathan C. Hwang†, Daniel Y. Kim, Kaelyn Nannini, Nhan V. Do, John M. Gaziano, Lee E. Wheless, Nathanael R. Fillmore‡, Rebecca I. Hartman‡† Equal first authorship · ‡ Equal senior authorship

Journal of the American Academy of Dermatology95(1), 240-243
U.S. Veterans and VA Data Retrospective Cohort Study Cancer-Associated Thrombosis Cutaneous Melanoma Overall Survival
2026

Risk and protective factors for uveal melanoma: Evidence for a protective role of autoimmune and immune-mediated conditions.

Charles Lu†, Debby Cheng†, Andrew Mu, Olivia Burke, Lirit Fuksman, Priya Katyal, Sara Khattab, Nga Nguyen, Emma Beagles, Crystal Chang, Suzanne Xu, Jonathan C. Hwang, Linden Huhmann, Nicholas Starink, Martin A. Weinstock, Maryam M. Asgari, Marc S. Hurlbert, John M. Gaziano, Nathanael R. Fillmore, Rebecca I. Hartman, Yevgeniy R. Semenov† Equal first authorship

Journal of the American Academy of Dermatology95(1), 211-214
U.S. Veterans and VA Data Case-Control Study Uveal Melanoma Cutaneous Melanoma Logistic Regression
2026

Parkinson's disease and risk of melanoma in United States veterans: A Veterans Affairs Cancer Registry retrospective cohort study.

Jonathan C. Hwang†, Linden B. Huhmann†, David Perez, Daniel Y. Kim, Kaelyn Nannini, Nhan V. Do, John M. Gaziano, Mary T. Brophy, Lee E. Wheless, Nathanael R. Fillmore‡, Rebecca I. Hartman‡† Equal first authorship · ‡ Equal senior authorship

Journal of the American Academy of Dermatology94(6), 1811-1814
U.S. Veterans and VA Data Retrospective Cohort Study VA Cancer Registry Parkinson's Disease Cutaneous Melanoma
2026

Identification of Risk Factors for Acral Melanoma in US Veterans.

Jonathan C. Hwang†, Linden B. Huhmann†, Kelly Cho, Sergey D. Goryachev, Nicholas Starink, Martin A. Weinstock, Maryam M. Asgari, Christy Zheng, Charles Lu, Theodore C. Feldman, Nhan V. Do, John M. Gaziano, Yevgeniy R. Semenov, Marc S. Hurlbert, Nathanael R. Fillmore‡, Rebecca I. Hartman‡† Equal first authorship · ‡ Equal senior authorship

JAMA Dermatology162(3), 279-291
Acral Melanoma Agent Orange Exposure U.S. Veterans and VA Data VA Cancer Registry Nested Case-Control Study
2025

The impact of imprecise case definitions in electronic health record research: a melanoma case-study from the Million Veteran Program.

Lee Wheless†, Dominique Mosley†, Daniel Dochtermann, Saiju Pyarajan, Katlyn Gonzalez, Rachel Weiss, Kyle Maas, Siwei Zhang, Lydia Yao, Yaomin Xu, Christopher Madden, Jacqueline Ike, Isabelle T. Smith, Sarah Grossarth, Otis Wilson, Adriana Hung, Nathanael R. Fillmore, Kevin Brown, Maria Teresa Landi, Rebecca I. Hartman, VA Million Veteran Program† Equal first authorship

Archives of Dermatological Research317(1), 308
Electronic Health Records Genome-Wide Association Study Million Veteran Program Cutaneous Melanoma Case Definition Validation
2024

Real-world effectiveness of immune checkpoint inhibitors and BRAF/MEK inhibitors among veteran patients with cutaneous melanoma.

Daniel Y. Kim, Susan M. Swetter, Linden Huhmann, Matthew P. Dizon, Jacqueline M. Ferguson, Thomas F. Osborne, Allyson C. Spence, Amina Ziad, Nathanael Fillmore‡, Rebecca I. Hartman‡‡ Equal senior authorship

Journal of the American Academy of Dermatology90(3), 620-623
U.S. Veterans and VA Data Retrospective Cohort Study Cutaneous Melanoma Immune Checkpoint Inhibitors BRAF/MEK Inhibitors
2022

Increased relative proportions of advanced melanoma among veterans: A comparative analysis with the Surveillance, Epidemiology, and End Results registry.

Michael S. Chang†, Jennifer La†, Nicole Trepanowski, David Cheng, John R. Bihn, Nhan Do, Mary Brophy, Nathanael R. Fillmore‡, Rebecca I. Hartman‡† Equal first authorship · ‡ Equal senior authorship

Journal of the American Academy of Dermatology87(1), 72-79
VA Cancer Registry SEER Database U.S. Veterans and VA Data Cutaneous Melanoma Melanoma Specific Survival